Unknown

Dataset Information

0

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.


ABSTRACT:

Background

Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma (HCC). One potential target is the Src family Kinase (SFK). C-Src, a non-receptor tyrosine kinase is a critical link of multiple signal pathways that regulate proliferation, invasion, survival, metastasis, and angiogenesis. In this study, we evaluated the effects of a novel SFK inhibitor, dasatinib (BMS-354825), on SFK/FAK/p130CAS, PI3K/PTEN/Akt/mTOR, Ras/Raf/MAPK and Stats pathways in 9 HCC cell lines.

Methods

Growth inhibition was assessed by MTS assay. EGFR, Src and downstream proteins FAK, Akt, MAPK42/44, Stat3 expressions were measured by western blot. Cell adhesion, migration and invasion were performed with and without dasatinib treatment.

Results

The IC50 of 9 cell lines ranged from 0.7 ?M?~?14.2 ?M. In general the growth inhibition by dasatinib was related to total Src (t-Src) and the ratio of activated Src (p-Src) to t-Src. There was good correlation of the sensitivity to dasatinib and the inhibition level of p-Src, p-FAK576/577 and p-Akt. No inhibition was found on Stat3 and MAPK42/44 in all cell lines. The inhibition of cell adhesion, migration and invasion were correlated with p-FAK inhibition.

Conclusion

Dasatinib inhibits the proliferation, adhesion, migration and invasion of HCC cells in vitro via inhibiting of Src tyrosine kinase and affecting SFK/FAK and PI3K/PTEN/Akt, but not Ras/Raf/MEK/ERK and JAK/Stat pathways. T-Src and p-Src/t-Src may be useful biomarkers to select HCC patients for dasatinib treatment.

SUBMITTER: Chang AY 

PROVIDER: S-EPMC3680296 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.

Chang Alex Y AY   Wang Miao M  

BMC cancer 20130530


<h4>Background</h4>Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma (HCC). One potential target is the Src family Kinase (SFK). C-Src, a non-receptor tyrosine kinase is a critical link of multiple signal pathways that regulate proliferation, invasion, survival, metastasis, and angiogenesis. In this study, we evaluated the effects of a novel SFK inhibitor, dasatinib (BMS-354825), on SFK/FAK/p130CAS, PI3K/PTEN/Akt/mTOR, Ras/Raf/MAPK and Stats pathways in  ...[more]

Similar Datasets

| S-EPMC5893260 | biostudies-literature
2011-10-27 | E-GEOD-27635 | biostudies-arrayexpress
| S-EPMC9166726 | biostudies-literature
2011-10-28 | GSE27635 | GEO
| S-EPMC3228144 | biostudies-literature
| S-EPMC8630445 | biostudies-literature
| S-EPMC7217836 | biostudies-literature
| S-EPMC10583560 | biostudies-literature
| S-EPMC3396621 | biostudies-literature
| S-EPMC6885881 | biostudies-literature